ADIAL PHARMACEUTICALS, INC. (ADIL)

Insider Trading Filed: 2026-04-09

CEO Cary J. Claiborne has been granted 37,985 restricted shares of Adial Pharmaceuticals' common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or a change of control event.
This insider grant suggests Claiborne's continued commitment to the company and alignment with shareholder interests through equity-based compensation.
The vesting schedule, tied to either time or a change of control, provides incentives for Claiborne to drive long-term value creation for Adial Pharmaceuticals.

Insider Trading Filed: 2026-04-09

The reporting person, Robertson H. Gilliland, received a grant of 9,185 shares of restricted common stock of Adial Pharmaceuticals, Inc. (ADIL), which vest in full on the earlier of one year from the grant date or upon a change of control.
The grant of restricted shares aligns the reporting person's interests with those of the company and its shareholders, as the vesting is tied to continued service and a potential change of control event.
The reporting person's direct ownership of 9,185 shares following the reported transaction represents a direct ownership stake in the company, indicating the reporting person's commitment to and confidence in Adial Pharmaceuticals' future.

Insider Trading Filed: 2026-04-09

Vinay Shah, the Chief Financial Officer of Adial Pharmaceuticals, acquired 17,325 shares of the company's common stock, which vest in full on the earlier of one year from the grant date or a change of control event.
This direct acquisition of shares by a key executive officer suggests their confidence in the company's future prospects and aligns their incentives with those of shareholders.
The vesting terms of the restricted stock grant, with accelerated vesting on a change of control, may indicate the company is positioning itself for a potential acquisition or other significant corporate event.

Insider Trading Filed: 2026-04-09

The reporting person, Kevin Schuyler, acquired 9,185 shares of common stock of ADIAL PHARMACEUTICALS, INC. (ADIL) at no cost, indicating an award or grant of restricted shares.
Schuyler also owns an additional 4 shares indirectly through his wife, Carolyn M. Schuyler, and 230 shares through MVA 151 Investors, LLC, which he controls.
The restricted share grant vests in full on the earlier of the one-year anniversary of the grant date or a change of control, subject to Schuyler's continued service to the company.

Current Report Filed: 2026-04-09

Adial Pharmaceuticals granted restricted stock awards to its named executive officers, including the CEO, CFO, and COO, as part of their compensation arrangements.
The restricted stock awards vest in full on the earlier of one year from the grant date or upon a change of control event, aligning the executives' interests with shareholders.
The company also granted restricted stock awards and stock options to its board of directors as compensation for their service, further strengthening the alignment between management, the board, and shareholders.

Insider Trading Filed: 2026-04-09

J. Kermit Anderson, a director of Adial Pharmaceuticals, Inc. (ADIL), has been granted 9,185 stock options on April 7, 2026, with a strike price of $1.64. The options vest in full on the earlier of the one-year anniversary of the grant date or a change of control event, subject to Anderson's continued service.
This stock option grant indicates that the company is incentivizing its directors, potentially to align their interests with those of shareholders and support the long-term growth of the business.
The timing of the grant, which is close to the filing date, suggests that the company may be experiencing a positive development or is preparing for a significant event, such as a change of control.

Insider Trading Filed: 2026-04-09

Tony Goodman, the Chief Operating Officer, acquired 26,510 shares of Adial Pharmaceuticals, Inc. (ADIL) common stock, representing a direct ownership increase of 0.13%.
The shares were granted as restricted stock with a one-year vesting period or upon a change of control event, aligning Goodman's interests with shareholders.
This insider buying activity suggests Goodman's confidence in the company's outlook and potential for value creation.

Current Report Filed: 2026-03-06

Adial Pharmaceuticals reported its financial results for the fiscal year ended December 31, 2025, providing investors with an update on the company's performance.
The press release attached to the 8-K filing contains the financial information, which investors can review to assess the company's financial health and growth trajectory.
As an emerging growth company, Adial Pharmaceuticals may have opted to use the extended transition period for complying with new or revised financial accounting standards, which could impact the comparability of its financial statements.

Important Information